Hypertension and insulin resistance: Role of peroxisome proliferator- activated receptor γ

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 7, 1999, Pages 558-560

  Itoh, Hiroshi ^a   Kentaro, Doi ^a   Tanaka, Tokuji ^a   Fukunaga, Yasutomo ^a   Hosoda, Kiminori ^b   Inoue, Gen ^a   Nishimura, Haruhiko ^a   Yoshimasa, Yasunao ^a   Yamori, Yukio ^b   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Adipocytes; Endothelial cells; Endothelin; Insulin resistance; Natriuretic peptides; Oxidative stress; Peroxisome proliferator activated receptor ; Risk factor; Syndrome X; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALITRETINOIN; ANTIDIABETIC AGENT; COMPLEMENTARY DNA; ENDOTHELIN; HYDROGEN PEROXIDE; INSULIN; MESSENGER RNA; NATRIURETIC PEPTIDE TYPE C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CONFERENCE PAPER; DIABETES MELLITUS; DRUG MECHANISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MOLECULAR CLONING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; RISK FACTOR; SYNDROME X; VASCULAR ENDOTHELIUM;

ADIPOSE TISSUE; ANIMALS; EPIDIDYMIS; GENE EXPRESSION; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MUSCLE, SMOOTH, VASCULAR; ORGAN SPECIFICITY; OXIDATIVE STRESS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 0032993595     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.03082.x     Document Type: Conference Paper

References (21)

1. 1. Reaven GM, Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
2. 2. Kaplan NM. The deadly quartet, upperbody obesity, glucose intolerance hypertriglyceridemia, and hypertension. Arch. Intern. Med. 1989; 149: 1514-20.
3. 3. Defronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
4. 4. Nakamura T, Tokunaga K, Shimomura I et al. Contribution of visceral fat accumulation to the development of coronary artery disease in nonobese men. Atherosclerosis 1994; 107: 239-46.
5. 5. Chang AY, Wyse BM, Gilchrist BJ, Keterson T, Diani AR. Ciglitazone, a new hypoglycemic agent, I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 1983; 32: 830-8.
6. 6. Fujita T, Sugiyama Y, Taketomi S et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyll-thiazolidine-2, 4-dione (ADD-3878, U-63, 287, eiglitazone), a new antidiabetic agent. Diabetes 1983; 32: 804-10.
7. 7. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 1994: 331: 1188-93.
8. 8. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of a new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-58.
9. 9. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 1995; 270: 12953-6.
10. 12,14-prostaglandin J2 is a ligand for the adipocyle determination factor PPARγ. Cell 1995; 83: 803-12.
11. 11. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPARγ 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994; 8: 1224-34.
12. 12. Lyons TJ, Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes: A carbonyl stress hypothesis. Diabetes Rev. 1997; 5: 365-91.
13. 13. Modan M, Halkins H, Almog S et al. Hyperinsulinemia: A link between hypertension, obesity and glucose intolerance. J. Clin. Invest. 1985; 75: 809-17.
14. 14. Ferrannini E, Buzzigoli R, Bonadonna R et al. Insulin resistance in essential hypertension. N. Engl. J. Med. 1987; 317: 350-7.
15. 15. Dzau VJ, Gibbons GH, Cooke JP, Omoigui N. Vascular biology and medicine in the 1990s: Scope, concepts, potentials and perspectives. Circulation 1993; 87: 705-19.
16. 16. Suga S, Nakao K, Iton H et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-β: Possible existence of 'vascular natriuretic peptide system'. J. Clin. Invest. 1992; 90: 1145-9.
17. 17. Komatsu Y, Nakao K, Itoh H, Suga S, Ogawa Y, Imura H. Vascular natriuretic peptide. Lancet 1992; 340: 622.
18. 18. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J. Clin. Invest. 1990; 86: 1690-7.
19. 19. Komatsu Y, Itoh H, Suga S et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells: Role of the vascular natriuretic peptide system in vascular growth inhibition. Circ. Res. 1996; 78: 606-14.
20. 20. Doi K, Itoh H, Ikeda T et al. Adenovirus-mediated gene transfer of C-type natriuretic peptide causes G1 growth inhibition of cultured vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 1997; 239: 889-94.
21. 21. Naruko T, Ueda M, van-der-Wal AC et al. C-type natriuretic peptide in human coronary atherosclerotic lesions. Circulation 1996; 94: 3103-8.